Employing this combination in an NSG animal model of prostate cancer xenograft they established that in the presence of HER2-CAR-T cells, the CAd-VECPDL1 virus’s expression of anti-PD-L1 antibody at the cancer site was considerably more efficacious at reducing cancer size [174]. Here, ERBB2 is linked to cancer.